Drug Database
Back to search

Iceland· IS-IS/1/16/034/01

Remurel

A glatiramer acetate product containing glatiramer acetat, registered in Iceland by Zentiva k.s.*. The same ATC class is registered in 14 of our 19 countries.

ATC L03AX13

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedRemurelATCL03AX13REGISTER NO.IS-IS/1/16/034/01PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about glatiramer acetatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Glatiramer acetate is registered in 14 of 19 countries.

Countries holding a registration under ATC L03AX13 (glatiramer acetate), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 10 of them publish a price we can compare per daily dose
Search glatiramer acetate products by name

Glatiramer acetate · ATC L03AX13

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Glatiramer acetat
Manufacturer
Zentiva k.s.*
Country
Iceland (IS)
ATC code
L03AX13
ATC class
Glatiramer acetate
Defined daily dose
20 mg, P
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 1

1 priced
  • ean
    025978
    28 áf.spr x1 pakki
    ISK 89920

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for glatiramer acetate.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check glatiramer acetate against other medicinesHow interaction checks work

Glatiramer acetate · interactions on record

2 records

  • 2 severe

Most severe, free to view

  • NatalizumabL04AA23severe
  • NatalizumabL04AG03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Glatiramer acetate in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glatiramer acetate products

Authorised across Europe · EMA

The same active substance is authorised in 1 EEA country. Names it is sold under:

  • France · Copaxone

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8f7c0d97-89bc-4b7a-a67b-5c6d13406efb
GET /v1/drugs/8f7c0d97-89bc-4b7a-a67b-5c6d13406efb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Stungulyf, lausn í áfylltri sprautu",
  "source": "lyfjastofnun",
  "atc_raw": "L03AX13",
  "marketed": true,
  "strength": "20 mg/ml",
  "ma_number": "IS/1/16/034/01",
  "substance": "Glatiramer acetat",
  "other_info": "Ávísun lyfsins er bundin við sérfræðinga í taugasjúkdómum með sérþekkingu og reynslu í meðferð á MS.",
  "legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
  "ma_issued_serial": "42550"
}
API referenceMCP serverPlans

See everything about glatiramer acetate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console